If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-18. Numbers and descriptions here follow the published literature rather than marketing material.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
== Contraindications == Dulaglutide should not be taken for patients with a personal family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2. Dulaglutide should also not be taken if there is a history of serious hypersensitivity to dulaglutide or any components within it. Dulaglutide injections may increase any risk of developing thyroid tumors including medullary thyroid carcinoma. Dulaglutide injection has caused thyroid tumors in rats, and it is unknown if this medication increases the risk of tumors in humans. If considering taking Dulaglutide, tell your doctor if anyone in your family has had Multiple Endocrine Neoplasia syndrome type 2 or thyroid cancer. If you experience any of the following symptoms, call your doctor immediately: a lump or swelling in the neck; hoarseness; difficulty swallowing; or shortness of breath The compound is also contraindicated in subjects with hypersensitivity to the active ingredient or any of the product's components.
Now differences between the contemporary squid and octopus samples became very clear. In the octopus, broad bands of fibers passed across the plane of the tissue and were separated by equally broad bands arranged in a perpendicular direction. In the squid there were narrower but also relatively broad bundles arranged in the plane of the section, separated by thin partitions of perpendicular fibers. It seemed I had found a means to identify the mystery sample after all. I could distinguish between octopus and squid, and between them and mammals, which display a lacy network of connective tissue fibers. After 75 years, the moment of truth was at hand. Viewing section after section of the St. Augustine samples, we decided at once, and beyond any doubt, that the sample was not whale blubber. Further, the connective tissue pattern was that of broad bands in the plane of the section with equally broad bands arranged perpendicularly, a structure similar to, if not identical with, that in my octopus sample. The evidence appears unmistakable that the St. Augustine sea monster was in fact an octopus, but the implications are fantastic. Even though the sea presents us from time to time with strange and astonishing phenomena, the idea of a gigantic octopus, with arms 75 to 100 feet in length and about 18 inches in diameter at the base—a total spread of some 200 feet—is difficult to comprehend.
In 1686, when the area was still a wilderness, New York's colonial governor, Thomas Dongan, designated the area now known as Bryant Park as a public space. George Washington's troops crossed the area while retreating from the Battle of Long Island in 1776. The road upon which Washington's troops retreated traversed the park site diagonally. The city acquired the land in 1822. Beginning in 1823, Bryant Park was designated a potter's field (a graveyard for the poor) and remained so until 1840, when thousands of bodies were moved to Wards Island. The first park at this site opened in 1847, though that park was never legally named. It was called "Reservoir Square" after the Croton Distributing Reservoir, which was erected on the eastern side of the park site due to its elevated location. In 1853, the Exhibition of the Industry of All Nations with the New York Crystal Palace, featuring thousands of exhibitors, took place in the park. The Crystal Palace, also known as the Great Exhibition Hall, burned down in 1858. The Latting Observatory was also constructed in the park as part of the 1853 Exhibition, and was also burned down in 1856. The square was used for military drills during the American Civil War, and was the site of some of the New York City draft riots of July 1863, when the Colored Orphan Asylum at Fifth Avenue and 43rd Street was burned down. Reservoir Square was renovated in 1870–1871, during which the modern-day park had been laid out. Several additional structures were planned for Reservoir Square, but never built.
Sources: en.wikipedia.org
==== Nocturnal enuresis ==== Children with OSA also show a higher risk for nocturnal enuresis and it is hypothesized to be caused by an excessive production of urine, impaired performance of the bladder and urethra or an inability to suppress the nocturnal bladder contraction, due to a failure to arouse. The risk for nocturnal enuresis increases with the severity of the sleep-disordered breathing: the more respiratory events per hour of sleep, the higher the risk for nocturnal enuresis. Obesity may also play a role, as it is associated with OSA and with nocturnal diuresis (due to an unhealthy diet). The interaction between OSA and obesity might thus result in nocturnal enuresis. Considering the high prevalence of nocturnal enuresis amongst children with sleep-disordered breathing, it is important to consider the latter in the differential diagnosis of nocturnal enuresis as the treatment of the sleep disorder might have a favourable therapeutic effect on the enuresis. For example, an adenotonsillectomy performed to reduce OSA has a positive impact on nocturnal enuresis. A study has shown that this surgery has a 60–75% chance to resolve the nocturnal enuresis completely, and an 80–85% chance to reduce its symptoms alongside other symptoms of OSA.
Mahathir's heavy-industrialisation programme also included Perwaja Steel, established in 1982 as a government-backed project to develop a domestic steel industry. The company subsequently accumulated substantial losses despite continued government support; a 2024 study in the Malaysian Journal of Economic Studies reported accumulated losses of RM9.9 billion between 1982 and its privatisation in 1996, rising to RM15 billion by the time operations ceased in 1999. Mahathir later described Perwaja as a miscalculation on his part while defending the broader record of his industrial policies. On the economic front, Mahathir inherited the New Economic Policy from his predecessors, which was designed to improve the economic position of the bumiputera—Malaysia's Malays and Indigenous peoples—via targets and affirmative action in areas such as corporate ownership and university admission. Like many of his economic liberal contemporaries such as British prime minister Margaret Thatcher, Mahathir actively pursued privatisation of government enterprises from the early 1980s. Mahathir believed this would provide economic opportunities for bumiputera and their businesses. His government privatised airlines, utilities and telecommunication firms, accelerating to a rate of about 50 privatisations a year by the mid-1990s. Privatisation generally improved the working conditions of Malaysians in privatised industries and raised significant revenue for the government.
=== Competition and other plant symbionts === Competition among EcM fungi is a well-documented case of soil microbial interactions. In some experiments, the timing of colonization by competing EcM fungi determined which species was dominant. Many biotic and abiotic factors can mediate competition among EcM fungi, such as temperature, soil pH, soil moisture, host specificity, and competitor number, and these factors interact with each other in a complex way. There is also some evidence for competition between EcM fungi and arbuscular mycorrhizal fungi. This is mostly noted in species that can host both EcM and AM fungi on their roots. Some soil bacteria, known as Mycorrhiza helper bacteria (MHBs), have been shown to stimulate EcM formation, root and shoot biomass, and fungal growth. Some argue that bacteria of this kind should be considered a third component of mycorrhizas. Other bacteria inhibit ectomycorrhizal formation.
Sources: en.wikipedia.org
=== Weight change === Metformin use is typically associated with weight loss. It appears to be safe and effective in counteracting the weight gain caused by the antipsychotic medications olanzapine and clozapine. Although modest reversal of clozapine-associated weight gain is found with metformin, primary prevention of weight gain is more valuable.
Gastric acid production is regulated by both the autonomic nervous system and several hormones. The parasympathetic nervous system, via the vagus nerve, and the hormone gastrin stimulate the parietal cell to produce gastric acid, both directly acting on parietal cells and indirectly, through the stimulation of the secretion of the hormone histamine from enterochromaffin-like cells (ECLs). Vasoactive intestinal peptide, cholecystokinin, and secretin all inhibit production. The production of gastric acid in the stomach is tightly regulated by positive regulators and negative feedback mechanisms. Four types of cells are involved in this process: parietal cells, G cells, D cells and enterochromaffin-like cells. Beside this, the endings of the vagus nerve (CN X) and the intramural nervous plexus in the digestive tract influence the secretion significantly. Nerve endings in the stomach secrete two stimulatory neurotransmitters: acetylcholine and gastrin-releasing peptide. Their action is both direct on parietal cells and mediated through the secretion of gastrin from G cells and histamine from enterochromaffin-like cells. Gastrin acts on parietal cells directly and indirectly too, by stimulating the release of histamine. The release of histamine is the most important positive regulation mechanism of the secretion of gastric acid in the stomach. Its release is stimulated by gastrin and acetylcholine and inhibited by somatostatin.
== Physical properties == All alkanes are colorless. The boiling points of the various hexanes are somewhat similar and, as for other alkanes, are generally lower for the more branched forms. The melting points are quite different and the trend is not apparent.
=== Research === TRH has been evaluated for the treatment of various neurological disorders. It has been attempted for treatment of various epileptic disorders. TRH has been shown to improve outcomes of CNS injuries in experimental models. Efficacy for the treatment ALS and spinal muscle atrophy has not been demonstrated. Many individuals with depression exhibit a blunted endocrine response to TRH due to unknown reasons, and the response is correlated with clinical outcomes. Involvement of TRH in the pathogenesis of depression has nevertheless not been well established. TRH has undergone research for its ostensible antidepressant properties, however, results regarding efficacy have been inconsistent. One study on a small sample of people with treatment-resistant depression found short-lived anti-depressant and anti-suicidal effects when TRH was administered intrathecally. An orally bioavailable prodrug is being researched. In 2012, the U.S. Army awarded a research grant to develop a TRH nasal spray for suicide prevention amongst veterans. TRH acts as a wakefulness-promoting agent, causing awakening from sleep or sedation.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.